Lexaria Bioscience Corp.
LEXX
$4.52
-$1.35-22.93%
NASDAQ
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 194.00K | 368.00K | 522.00K | 705.90K | 615.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 194.00K | 368.00K | 522.00K | 705.90K | 615.90K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 2.70K | 2.70K |
| Gross Profit | 194.00K | 368.00K | 522.00K | 703.20K | 613.20K |
| SG&A Expenses | 3.69M | 3.87M | 4.12M | 4.13M | 4.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.69M | 9.62M | 11.07M | 12.37M | 12.01M |
| Operating Income | -7.49M | -9.25M | -10.55M | -11.67M | -11.40M |
| Income Before Tax | -7.74M | -9.53M | -10.80M | -11.91M | -11.40M |
| Income Tax Expenses | 4.40K | 4.40K | 1.80K | -- | -- |
| Earnings from Continuing Operations | -7.74 | -9.54 | -10.80 | -11.91 | -11.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 8.50K | 8.20K | 9.20K | 9.60K | 10.00K |
| Net Income | -7.73M | -9.53M | -10.79M | -11.90M | -11.39M |
| EBIT | -7.49M | -9.25M | -10.55M | -11.67M | -11.40M |
| EBITDA | -7.42M | -9.16M | -10.48M | -11.58M | -11.31M |
| EPS Basic | -0.35 | -0.48 | -0.57 | -0.66 | -0.66 |
| Normalized Basic EPS | -0.21 | -0.29 | -0.35 | -0.41 | -0.41 |
| EPS Diluted | -0.35 | -0.48 | -0.57 | -0.66 | -0.66 |
| Normalized Diluted EPS | -0.21 | -0.29 | -0.35 | -0.41 | -0.41 |
| Average Basic Shares Outstanding | 90.20M | 83.69M | 76.76M | 72.06M | 68.19M |
| Average Diluted Shares Outstanding | 90.20M | 83.69M | 76.76M | 72.06M | 68.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |